K. Höffken

发表

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.

T. Kroll, I. Runnebaum, K. Pachmann, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plagiarism and other scientific misconducts

K. Höffken, H. Gabbert, 2009, Journal of Cancer Research and Clinical Oncology.

Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring

U. Schneider, K. Pachmann, O. Camara, 2005, Breast Cancer Research.

Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC® is a predictor for relapse: A preliminary report

Katharina Pachmann, K. Pachmann, U. Pachmann, 2005, World journal of surgical oncology.

Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls

K. Kliche, J. Clement, K. Höffken, 2002, Journal of Cancer Research and Clinical Oncology.

Invasive bronchopulmonary aspergillosis leading to rapidly progessive respiratory failure in a patient with severe aplastic anemia

C. Schmidt, K. Höffken, H. Höfeler, 1987, Klinische Wochenschrift.

Serum Cytokine Levels in Cancer Patients Treated with Different Schedules of Ultra‐Low-Dose Interleukin‐2

V. Diehl, R. Mertelsmann, P. Brossart, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Care of breast cancer in the elderly woman—what does comprehensive geriatric assessment (CGA) help?

K. Höffken, U. Wedding, 2003, Supportive Care in Cancer.

Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.

S. Scholl, J. Clement, K. Höffken, 2005, The Journal of laboratory and clinical medicine.

Lack of regeneration of myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans with large anterior myocardial infarctions.

H. Figulla, K. Höffken, H. Sayer, 2004, International journal of cardiology.

Mobilization of stem cells by granulocyte colony-stimulating factor for the regeneration of myocardial tissue after myocardial infarction

H. Figulla, K. Höffken, T. Opfermann, 2004, Deutsche medizinische Wochenschrift.

Chemotherapy in stage II testicular tumours

C. Schmidt, K. Höffken, 1976, Zeitschrift für Krebsforschung und Klinische Onkologie.

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.

W. Jonat, K. Possinger, K. Höffken, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacoeconomic evaluation of high-dose chemotherapy and peripheral blood stem cell support in high-risk or poor-prognosis malignancies

K. Höffken, R. Kath, M. Hartmann, 1998, Journal of Cancer Research and Clinical Oncology.

The European experience.

K. Höffken, K. Höffken, Klaus Höffken, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Social support and survival in patients with acute myeloid leukaemia

M. Pinquart, R. Silbereisen, K. Höffken, 2006, Supportive Care in Cancer.

Docetaxel for advanced gastric cancer?

O. Kuss, K. Höffken, U. Wedding, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of LH-RH analogues in the adjuvant and palliative treatment of breast cancer.

K. Höffken, R. Kath, 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

LH-RH agonists in the treatment of premenopausal patients with advanced breast cancer.

K. Höffken, 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

New Approaches in the Hormonal Therapy of Breast Cancer

K. Höffken, 1989 .

Buserelin in the Treatment of Premenopausal Patients with Advanced Breast Cancer

E. Kurschel, C. Schmidt, K. Höffken, 1988 .

Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor

J. Clement, K. Höffken, J. Sänger, 1999, International journal of cancer.

Selective reduction of the interaction of magnetic nanoparticles with leukocytes and tumor cells by human plasma

N. Buske, J. Clement, K. Pachmann, 2005 .

Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous‐cell carcinoma

H. Gabbert, M. Sarbia, J. Clement, 1999, International journal of cancer.

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

V. Diehl, F. Herrmann, J. Kolitz, 2004, Cancer Immunology, Immunotherapy.

Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT

S. Scholl, K. Pachmann, K. Höffken, 2005, Bone Marrow Transplantation.

ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.

S. Scholl, J. Clement, K. Höffken, 2006, Leukemia research.

Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells.

A. Harris, Jingwen Liu, P. Hortschansky, 2004, International journal of oncology.

Premenopausal breast cancer: chemotherapy and endocrine therapy.

K. Kliche, K. Höffken, H. Sayer, 2002, Drugs.

Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer

K. Höffken, H. Sayer, R. Kath, 2003, Journal of Cancer Research and Clinical Oncology.

Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer

C. Schmidt, K. Höffken, Antonius A. Miller, 2004, Cancer Chemotherapy and Pharmacology.

Experience with aromatase inhibitors in the treatment of advanced breast cancer.

K. Höffken, 1993, Cancer treatment reviews.

BRCA1 mutations and phenotype

S. Scherneck, K. Höffken, R. Kath, 2005, Journal of Cancer Research and Clinical Oncology.

[Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)].

S. Seeber, C. Schmidt, K. Höffken, 1976, Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology.

Cytokine Serum Levels During the Course of Acute Myeloid Leukemia

M. Stauch, K. Höffken, D. Fritsche, 1997 .

Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study

V. Diehl, R. Mertelsmann, P. Brossart, 1993, Cancer Immunology, Immunotherapy.

Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results.

K. Höffken, U. Wedding, U. Merkel, 2003, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.

K. Kliche, K. Höffken, M. Raida, 2002, Journal of Cancer Research and Clinical Oncology.

Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells

K. Höffken, H. Sayer, W. Vogel, 1998, Journal of Cancer Research and Clinical Oncology.

[Geriatric oncology].

K. Höffken, U. Wedding, 2000, Zeitschrift fur arztliche Fortbildung und Qualitatssicherung.

Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase γ

S. Scholl, R. Wetzker, J. Clement, 2008, Journal of Cancer Research and Clinical Oncology.

Bone morphogenetic protein 2 (BMP-2) induces sequential changes of Id gene expression in the breast cancer cell line MCF-7

S. Wölfl, K. Kliche, W. Sebald, 2000, Journal of Cancer Research and Clinical Oncology.

Differential expression of cancer-related genes by single and permanent exposure to bone morphogenetic protein 2

S. Wölfl, T. Kroll, P. Hortschansky, 2008, Journal of Cancer Research and Clinical Oncology.

Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study.

A. Ganser, A. Grothey, M. Flasshove, 1990, Onkologie.

Current treatment options in dermatofibrosarcoma protuberans

T. Mentzel, K. Höffken, L. Mügge, 2009, Journal of Cancer Research and Clinical Oncology.

The role of apoptosis in hematologic malignancies and modulation of apoptosis as a new therapeutic approach

K. Kliche, K. Höffken, 1999, Journal of Cancer Research and Clinical Oncology.

ELECTROPORATION STIMULATES INTERLEUKIN 10 PRODUCTION IN HUMAN MONOCYTIC CELL LINES THP-1 AND U937

H. Berg, K. Höffken, M. H. Lehmann, 1996 .

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor

W. Siegert, G. Ehninger, K. Höffken, 2003, Bone Marrow Transplantation.

Gastric cancer in very young adults: apropos four patients and a review of the literature

K. Höffken, J. Fiehler, R. Kath, 2000, Journal of Cancer Research and Clinical Oncology.

The neu-oncogene product in serum and tissue of patients with breast carcinoma.

S. Seeber, M. Scheulen, K. Höffken, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Improvement of the separation of tumour cells from peripheral blood cells using magnetic nanoparticles

Joachim H. Clement, Katharina Pachmann, J. Clement, 2006 .

Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells

K. Kliche, W. Weitschies, M. Schnabelrauch, 2006, Journal of Cancer Research and Clinical Oncology.

One hundred years of cancer research

K. Höffken, 2004, Journal of Cancer Research and Clinical Oncology.

Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation

K. Kliche, S. Scholl, J. Clement, 2004, Journal of Cancer Research and Clinical Oncology.

174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML

A. Ganser, F. Herrmann, W. Hofmann, 1997 .

Severe non-haematological toxicity after treatment with gemcitabine

K. Höffken, A. Sauer-Heilborn, R. Kath, 1999, Journal of Cancer Research and Clinical Oncology.

Treatment of high-risk, nonseminomatous testicular cancer with cisplatin, ifosfamide and bleomycin: long-term results.

S. Seeber, M. Scheulen, N. Niederle, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Theneu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas

H. Kosmehl, K. Höffken, W. Vogel, 2005, Journal of Cancer Research and Clinical Oncology.

Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.

C. Schmidt, K. Höffken, H. Kley, 1986, Cancer treatment reports.

Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.

S. Scholl, J. Clement, K. Höffken, 2005, Leukemia research.

Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation – successful treatment with high-dose methylprednisolone and defibrotide

K. Höffken, H. Sayer, K. Schilling, 2002, Journal of Cancer Research and Clinical Oncology.

Antimicrobial therapy of unexplained fever in neutropenic patients

O. Sezer, K. Höffken, W. Kern, 2003, Annals of Hematology.

Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin Ara-C, VP-16, Followed by G-CSF-Priming Exhibits High Remission Rate

A. Ganser, F. Herrmann, W. Hofmann, 1998 .

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma

G. Riethmüller, R. Pichlmayr, K. Höffken, 1994, The Lancet.

Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes.

V. Diehl, A. Ganser, B. Lathan, 1990, Haematology and blood transfusion.

Immunogenicity of cellular and acellular antigen preparations from a methylcholanthrene-induced mouse sarcoma

C. Schmidt, K. Höffken, U. Steih, 2004, Journal of Cancer Research and Clinical Oncology.

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

A. Ganser, W. Hofmann, K. Höffken, 1999, Annals of Hematology.

Magnetic nanoparticles coated with carboxymethylated polysaccharide shells—Interaction with human cells

T. Kroll, R. Muller, M. Schnabelrauch, 2009 .

Dissociation and isolation of antigen and antibody from immune complexes.

C. Schmidt, K. Höffken, F. Bosse, 1982, Journal of immunological methods.

Standardized quantification of circulating peripheral tumor cells from lung and breast cancer

Katharina Pachmann, Oumar Camara, J. Clement, 2005, Clinical chemistry and laboratory medicine.

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

A. Ganser, W. Hofmann, W. Brockhaus, 2000, Annals of Hematology.

Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients

B. Röhrig, K. Höffken, L. Pientka, 2007, Journal of Cancer Research and Clinical Oncology.

BRCA1 mutations in German breast‐cancer families

P. Schlag, S. Seitz, B. Jandrig, 1996, International journal of cancer.

Prognosis and treatment of disseminated uveal melanoma

N. Bornfeld, S. Seeber, K. Höffken, 1993, Cancer.

Multicolor-FISH applied to resolve complex chromosomal changes in a case of T-ALL (FAB L2)

T. Liehr, K. Höffken, R. Aroutiounian, 2006, Cytogenetic and Genome Research.

Retrovirus mediated gene transfer into hemopoietic cells

H. V. Melchner, K. Höffken, 1988, Blut: Zeitschrift für die Gesamte Blutforschung.

Novel cryptic chromosomal rearrangements detected in acute lymphoblastic leukemia detected by application of new multicolor fluorescent in situ hybridization approaches.

T. Liehr, K. Höffken, U. Wedding, 2006, International journal of oncology.

Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.

A. Ganser, F. Herrmann, R. Mertelsmann, 1990, Blood.

Primary gastric non-Hodgkin's lymphoma: a clinicopathological study of 41 patients

K. Donhuijsen, S. Seeber, K. Höffken, 2005, Journal of Cancer Research and Clinical Oncology.

IMMUNE COMPLEXES AND PROGNOSIS OF HUMAN BREAST CANCER

R. W. Baldwin, R. Blamey, K. Höffken, 1978, The Lancet.

Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

T. Ittel, R. Naumann, K. Höffken, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical implications of molecular genetic aberrations in acute myeloid leukemia

S. Scholl, K. Höffken, H. Sayer, 2009, Journal of Cancer Research and Clinical Oncology.

CHROMOSOME ABNORMALITIES IN ANGIOIMMUNOBLASTIC LYMPHADENOPATHY

C. Schmidt, K. Höffken, D. Hossfeld, 1976, The Lancet.

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

F. Herrmann, R. Mertelsmann, A. Lindemann, 1990 .

Journal of Cancer Research and Clinical Oncology

F. Lordick, K. Höffken, 2021, Forum.

Safety and impact of donor‐type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch

S. Scholl, K. Höffken, H. Sayer, 2005, Transfusion.

T lymphocyte-mediated graft--antigraft reactivity during graft-versus-host reaction in vitro.

H. von Melchner, K. Höffken, 1984, Blood.

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Aplastic Anemia: A Phase I/II Trial with Emphasis on Very Severe Neutropenia and Active Infection

H. Heimpel, F. Herrmann, K. Höffken, 1992 .

Commitment to differentiation of human promyelocytic leukemia cells (HL60): An all‐or‐none event preceded by reversible losses of self‐renewal potential

H. von Melchner, K. Höffken, 1985, Journal of cellular physiology.

Formestane in the treatment of advanced postmenopausal breast cancer.

W. Jonat, K. Possinger, K. Höffken, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

LH-RH Agonists in Oncology

K. Höffken, 1988, Springer Berlin Heidelberg.

Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia.

S. Scholl, O. Landt, J. Clement, 2007, Leukemia research.

Requestioning depression in patients with cancer: contribution of somatic and affective symptoms to Beck's Depression Inventory.

B. Röhrig, K. Höffken, L. Pientka, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.

D. Wallwiener, A. Ebert, N. Harbeck, 2004, European journal of cancer.

Tolerance to chemotherapy in elderly patients with cancer.

C. Bokemeyer, K. Höffken, F. Honecker, 2007, Cancer control : journal of the Moffitt Cancer Center.

Premenopausal Breast Cancer

K. Kliche, K. Höffken, H. Sayer, 2012, Drugs.

[Paraneoplastic pityriasis rubra pilaris in metastatic adenocarcinoma without diagnosable primary].

U. Müller, K. Höffken, C. Kloos, 2002, Deutsche medizinische Wochenschrift.

Flt3-ITD mutations can generate leukaemia specific neoepitopes: Potential role for immunotherapeutic approaches

S. Scholl, K. Höffken, A. Kaufmann, 2006, Leukemia & lymphoma.

Disconnection of genes coding for self-renewal and differentiation: A possible mechanism of diversity in acute myeloid leukemias

H. V. Melchner, K. Höffken, 1985, Blut.

Changes in self‐renewal potential of human leukemic cells (K562): A bidirectional stochastic process

H. von Melchner, K. Höffken, 1985, Journal of cellular physiology.

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors

S. Scholl, K. Höffken, H. Sayer, 2004, Bone Marrow Transplantation.

Distinct reconstitution of neutrophil functions after allogeneic peripheral blood stem cell transplantation

S. Scholl, K. Höffken, H. Sayer, 2007, Journal of Cancer Research and Clinical Oncology.

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia

S. Scholl, K. Höffken, V. Scheble, 2008, European journal of haematology.

Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia

S. Scholl, K. Höffken, L. Mügge, 2007, Annals of Hematology.

Quantitation of immune complexes by nephelometry.

C. Schmidt, K. Höffken, U. Bestek, 1979, Journal of immunological methods.

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia

K. Höffken, R. Kath, H. Fricke, 2001, Journal of Cancer Research and Clinical Oncology.

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

J. Witte, W. Schmiegel, G. Schlimok, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].

K. Höffken, R. Kath, H. Peters, 2001, Deutsche medizinische Wochenschrift.

Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

A. V. van Kuilenburg, K. Höffken, A. H. Gennip, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Breast cancer imaging with radioiodinated oestradiol

O. Schober, C. Jackisch, C. Reiners, 1990, The Lancet.

Molecular characterization of breast cancer cell lines by expression profiling

S. Wölfl, T. Kroll, C. Platzer, 2002, Journal of Cancer Research and Clinical Oncology.

Impairment in functional status and survival in patients with acute myeloid leukaemia

B. Röhrig, K. Höffken, H. Sayer, 2006, Journal of Cancer Research and Clinical Oncology.

Etoposide in the treatment of refractory breast cancer.

K. Höffken, 1982, Cancer treatment reviews.

Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.

R. Osieka, C. Schmidt, K. Höffken, 1989, Acta oncologica.

Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer

K. Höffken, C. Schneider, A. Klippstein, 2003, Journal of Cancer Research and Clinical Oncology.

Impaired granulocytic function in patients with acute leukaemia: only partial normalisation after successful remission-inducing treatment

M. Stauch, K. Höffken, W. Hofmann, 1998, Journal of Cancer Research and Clinical Oncology.

Allogeneic blood stem cell transplantation in advanced chronic myeloid leukemia--high response rate associated with increased chronic graft-versus-host disease.

S. Scholl, K. Höffken, H. Sayer, 2003, Haematologica.

Preferred co-localization of chromosome 8 and 21 in myeloid bone marrow cells detected by three dimensional molecular cytogenetics.

A. Lier, K. Mrasek, T. Liehr, 2009, International journal of molecular medicine.

Quality-of-life in elderly patients with cancer: a short review.

K. Höffken, L. Pientka, U. Wedding, 2007, European journal of cancer.

B. Röhrig, K. Höffken, U. Wedding, 2009, European journal of cancer care.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

A phase II study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly alternating doxorubicin and cisplatin for advanced gastric carcinoma

K. Höffken, G. Kähler, J. Scheele, 1998, Journal of Cancer Research and Clinical Oncology.

[Cardiac manifestations of peripheral primitive neuroectodermal tumor (pPNET): a rare case].

K. Höffken, D. Katenkamp, R. Kath, 2000, Deutsche medizinische Wochenschrift.

Acute Abdomen by Varicella Zoster Virus Induced Gastritis after Autologous Peripheral Blood Stem Cell Transplantation in a Patient with Non-Hodgkin’s Lymphoma

S. Scholl, K. Höffken, M. Hocke, 2006, Acta Haematologica.

Malignancies in patients with insulin-treated diabetes mellitus

U. Müller, K. Höffken, R. Schiel, 2000, Journal of Cancer Research and Clinical Oncology.

[Immune complexes in malignant diseases: tumor markers or epiphenomena?].

C. Schmidt, K. Höffken, 2008, Deutsche medizinische Wochenschrift.

Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy

B. Röhrig, K. Höffken, L. Pientka, 2008, Acta oncologica.

Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients.

C. Schmidt, K. Höffken, H. Olbrich, 1991, Onkologie.

Breast cancer patients' expectations in respect of the physician-patient relationship and treatment management results of a survey of 617 patients.

W. Lehmacher, D. Wallwiener, G. von Minckwitz, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy of Disseminated Non-Seminomatous Testicular Cancer and Metastatic Seminoma with Ifosfamide/Mesna1

S. Seeber, M. Scheulen, N. Niederle, 1987 .

Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid leukemia with normal GTG-banding karyotype.

T. Liehr, K. Höffken, H. Mkrtchyan, 2009, International journal of oncology.

Gemcitabine Combined With Epirubicin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer: A Phase II Study

D. Wallwiener, K. Krejcy, H. Hausmaninger, 2004, American journal of clinical oncology.

B. Röhrig, K. Höffken, L. Pientka, 2007, Journal of Cancer Research and Clinical Oncology.

Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine

R. Semrau, K. Höffken, K. Merkle, 2002, Journal of Cancer Research and Clinical Oncology.

Isolated brain metastases as the sole manifestation of a late relapse in breast cancer

R. Semrau, K. Höffken, R. Kath, 2002, Journal of Cancer Research and Clinical Oncology.

The significance of somatostatin analogues in the antiproliferative treatment of carcinomas.

K. Höffken, R. Kath, 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Meningeal fluid granulocytosis after cytarabine.

S. Seeber, M. Flasshove, K. Höffken, 1992, European journal of cancer.

Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study

S. Seeber, K. Höffken, K. Ridwelski, 1998, Journal of Cancer Research and Clinical Oncology.

Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients

B. Röhrig, K. Höffken, L. Pientka, 2007, Supportive Care in Cancer.

Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale.

K. Höffken, L. Pientka, U. Wedding, 2007, Critical reviews in oncology/hematology.

Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.

K. Höffken, U. Merkel, R. Kath, 2002, Journal of Cancer Research and Clinical Oncology.

The Carboxymethyl Dextran Shell is an Important Modulator of Magnetic Nanoparticle Uptake in Human Cells

N. Buske, J. Clement, K. Pachmann, 2006 .

R. W. Baldwin, P. McLaughlin, M. Price, 1978, Immunochemistry.

Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up

A. Ganser, W. Hofmann, W. Brockhaus, 1998 .

Circulating immune complexes in rats bearing chemically induced tumors. I. Sequential determination during the growth of tumours at various body sites

R. W. Baldwin, P. McLaughlin, M. Price, 1978, International journal of cancer.

Differential expression and regulation of bone morphogenetic protein 7 in breast cancer.

J. Clement, K. Höffken, J. Sänger, 2003, International journal of oncology.

Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations

S. Scholl, K. Höffken, F. von Eggeling, 2007, Leukemia & lymphoma.

Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.

K. Höffken, M. Hippius, U. Wedding, 2006, International journal of clinical pharmacology and therapeutics.

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.

T. Kroll, I. Runnebaum, K. Pachmann, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen

C. Schmidt, K. Höffken, R. Becher, 1989, Cancer.